Hansa Biopharma AB Share Price

Equities

HNSA

SE0002148817

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm 16:29:58 26/04/2024 BST 5-day change 1st Jan Change
27.32 SEK +0.44% Intraday chart for Hansa Biopharma AB -6.76% +4.27%

Financials

Sales 2024 * 239M 21.87M 1.75B Sales 2025 * 343M 31.32M 2.51B Capitalization 1.5B 137M 11B
Net income 2024 * -735M -67.18M -5.38B Net income 2025 * -712M -65.08M -5.21B EV / Sales 2024 * 8.27 x
Net Debt 2024 * 474M 43.33M 3.47B Net Debt 2025 * 733M 67.04M 5.37B EV / Sales 2025 * 6.53 x
P/E ratio 2024 *
-2.37 x
P/E ratio 2025 *
-2.81 x
Employees 166
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.44%
1 week-6.76%
Current month-6.12%
1 month-5.79%
3 months-14.62%
6 months+11.88%
Current year+4.27%
More quotes
1 week
25.90
Extreme 25.9
30.00
1 month
25.90
Extreme 25.9
33.36
Current year
25.00
Extreme 25
40.50
1 year
20.14
Extreme 20.14
58.10
3 years
20.14
Extreme 20.14
178.20
5 years
20.14
Extreme 20.14
288.60
10 years
11.80
Extreme 11.8
349.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 19/03/18
Chief Tech/Sci/R&D Officer 53 11-30
Chief Tech/Sci/R&D Officer 66 28/05/20
Members of the board TitleAgeSince
Director/Board Member 73 28/05/18
Chairman 61 29/06/22
Director/Board Member 59 21/05/19
More insiders
Date Price Change Volume
26/04/24 27.32 +0.44% 257,784
25/04/24 27.2 -2.44% 200,908
24/04/24 27.88 -0.29% 98,780
23/04/24 27.96 -0.64% 98,303
22/04/24 28.14 -3.96% 163,345

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:29 pm

More quotes
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
27.32 SEK
Average target price
105 SEK
Spread / Average Target
+284.33%
Consensus